ALL News

Series B led by a renowned family office focused on life sciences, with impact-focused VC Revent as co-investor, plus support from existing investorsFurther development of proprietary DISQVER® technology and international expansion Duisburg, May 16, 2022 –...

Noscendo is committed to supporting physicians, clinics and laboratories in their daily work in the field of pathogen detection and to provide therapy-relevant results that directly benefit patients. With its groundbreaking diagnostic platform DISQVER®, Noscendo helps save patients' lives through highly accurate pathogen detection.

SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve as process controls to ensure highest process quality and validity for patient samples.

In hospitals in Germany, infections are one of the greatest challenges. So-called sepsis, colloquially also known as blood poisoning, accounts for a major portion of these infections. According to a study by Jena University Hospital, nationwide 320,000 people develop sepsis, and one quarter of those affected die of the sequelae. This analysis implies that in the state of Rhineland-Palatinate almost 16,000 people will fall ill with sepsis each year. The faster and the more effectively the responsible germs can be fought, the faster the patient will recover. This also means that life-saving intensive care beds become available again more quickly, which is of major importance during the current corona pandemic. “Thanks to a new contract of Mainz University Medical Centre with software company Noscendo and TK health insurance, a new software-based method comprising a special test and a pathogen platform can now be used to identify the causative pathogens. This means that it is possible to help those insured with us more quickly and more effectively,” rejoices Jörn Simon, director of TK’s state office in Rhineland-Palatinate

Noscendo GmbH arrives at TTR in Reutlingen with innovative diagnostics platform Rapid results cure patients and relieve pressure on hospitals (Stuttgart/Reutlingen) – Noscendo GmbH recently opened a branch at the Reutlingen site of the Tübingen-Reutlingen Technology Park (TTR). Its state-of-the-art development and application laboratory identifies the causes of numerous infectious diseases exceptionally fast using next-generation sequencing (NGS) based on the company’s own diagnostics platform, which reliably detects bacteria, DNA viruses, fungi and parasites in patients’ blood samples. In intensive care medicine, obtaining…

Noscendo GmbH, a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections, today announced the commencement of operations in its own development and application laboratory as well as the closing of a financing round. Renowned new investors including Earlybird, Paua Ventures and the JIH Family Office joined the round while existing investors, such as Wieland Capital and High-Tech Gründerfonds, continued to invest.

Noscendo GmbH and the University Hospital Bonn (UKB) today announced the successful signing of a cooperative agreement with the Institute for Hygiene and Public Health (IHPH) at the UKB, working towards expansion of the proprietary and CE-certified diagnostic platform DISQVER® in the field of microbial resistances. Through the partnership, Noscendo GmbH will fully molecularly characterise up to 8000 antibiotic-resistant pathogens from over 35 species using the latest sequencing technology. The institute’s strain bank, which has been running for 20 years and is continually growing, and the environmental databank are fed from various national and international projects and their structure addresses significant resistance problems of today’s inpatient treatments.

Noscendo GmbH today announced the successful completion of the development of its proprietary diagnostic platform DISQVER® combined with corresponding CE certification as the first key milestone since the seed financing in October 2018. Noscendo’s platform detects bacteria, fungi, DNA viruses and parasites in the patient’s bloodstream on the basis of next-generation sequencing (NGS) and uses proprietary algorithms to assess the corresponding pathogen relevance

In two-thirds of all cases, existing diagnostic procedures do not allow intensive care clinicians to draw conclusions on the pathogens causing bloodstream associated infections such as sepsis (“blood poisoning”) and endocarditis (inflammation of the inner layers of the heart). Therapy options are therefore very often limited to administering broad-band antibiotics. Unspecific therapy leads to high mortality rates and severe complications in many patients, and also accentuates the issue of resistant hospital pathogens.